Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Shah, Riyaz
ADEPPT, NCT05673187 / 2022-002736-31: Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status	Recruiting	2	68	Europe	Adagrasib	ETOP IBCSG Partners Foundation, Mirati Therapeutics Inc.	NSCLC Stage IV, KRAS P.G12C	10/25	03/26
AMAZE-lung, NCT05601973 / 2021-002337-42: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI	Recruiting	2	60	Europe	Amivantamab, Lazertinib, Zirabev	ETOP IBCSG Partners Foundation, Janssen Pharmaceuticals	Non Small Cell Lung Cancer	03/26	09/26